# Corbion account plan

> Corbion is a Dutch fermentation-based food-ingredient company (lactic acid, natural preservation, algae omega-3) with € 1,267.4 million sales in 2025.

## At a glance

Corbion is a Euronext Amsterdam-listed company that makes food-ingredient solutions from fermentation: lactic acid and derivatives, natural food preservation, functional ingredient systems and algae-derived omega-3. It sells to food manufacturers, industrial, pharma and medical customers through sales offices and distributors, with plants in the US, Thailand, Brazil, Mexico, the Netherlands and Spain and headquarters in the Netherlands. In 2025 sales were € 1,267.4 million (+2.2% organic), adjusted EBITDA € 204.3 million (16.1% margin) and result after taxes € 74.8 million, with a workforce of 2,408 FTE. The US was its largest market at € 460.7 million of sales.

## Business units

- **Functional Ingredients & Solutions - Food** (€ 741.9 million 2025 sales (about 58% of group, computed)): Fermentation- and vinegar-based preservation, lactates, natural mold inhibitors, dairy stabilizers and protein fortification for bakery, meat, seafood, dairy, sauces and pet food makers. Bakery and meat demand was soft in 2025, while natural mold inhibitors, vinegars and high-protein bread grew; capacity was added in Montgomery (US) and Querétaro (Mexico).
- **Functional Ingredients & Solutions - Biochemicals** (€ 146.9 million 2025 sales (about 12% of group, computed)): Lactic acid and derivatives for industrial markets such as home and personal care and electronics, supplied by the circular lactic acid plant in Rayong, Thailand. Sales dipped in 2025 but grew strongly in the first nine months of 2026.
- **Functional Ingredients & Solutions - Lactic Acid to PLA JV** (€ 81.6 million 2025 sales (about 6% of group, computed)): High-purity lactic acid sold to TotalEnergies Corbion, the 50/50 joint venture making Luminy PLA. Corbion ran a sale process for its stake but ended it in October 2026 because offers did not reflect the business's value; JV sales rose 24.2% organically in the first nine months of 2026.
- **Health & Nutrition - Nutrition** (€ 154.2 million 2025 sales (about 12% of group, computed)): Algae-derived omega-3 (AlgaPrime DHA for aquaculture and pets, AlgaVia for human nutrition), produced at Orindiúva, Brazil. Growth is driven by aquafeed partners, with diversification into pet and human nutrition as fish-oil prices climb.
- **Health & Nutrition - Pharma** (€ 80.3 million 2025 sales (about 6% of group, computed)): Lactic-acid-derived pharmaceutical ingredients (PURASAL) made under cGMP for renal and acute care. Volume/mix grew in 2025 but 2026 sales fell on destocking at key customers in North and Latin America.
- **Health & Nutrition - Biomaterials** (€ 62.5 million 2025 sales (about 5% of group, computed)): Resorbable PURASORB polymers for long-acting injectables, orthopedics, wound closure and aesthetics. It posted strong double-digit growth in 2025, and the FDA approved the Teva/Medincell once-monthly olanzapine injectable WELTRUZA in October 2026.

## Strategic priorities

- **BRIGHT 2030 targets**: Announced in November 2025: 3-6% organic sales growth per year, adjusted EBITDA margin of approximately 18% by 2028, € 270 million cumulative free cash flow over 2026-2028 and 13% ROCE.
- **Natural and label-friendly preservation**: Grow in natural mold inhibitors, vinegars and Listeria control (with AI-driven modeling) as customers reformulate and EU Listeria legislation tightens in summer 2026; the report sizes the natural food preservation market at € 1.6 billion, growing 4-5% a year.
- **Omega-3 beyond aquaculture**: Diversify algae omega-3 into pet food, human nutrition and products such as astaxanthin, and renegotiate long-term aquaculture contracts ending in December 2026 at higher prices.
- **Grow Biomaterials**: Expand resorbable polymers in drug delivery, orthopedics and aesthetics, supported by the WELTRUZA approval.
- **Margin through input costs and mix**: Levers to an 18% margin are input costs (sugar hedged for 2027 and early 2028), faster growth in H&N specialties and returns on the Thai lactic acid plant, while reducing non-core lactic acid exposures.

## Latest results

In Q3 2026 sales were € 340.5 million (+9.3% reported, +7.6% organic) and adjusted EBITDA € 64.1 million, a margin of 18.8% versus 15.9% a year earlier. Health & Nutrition grew 20.0% organically in the quarter as Nutrition volumes phased from the first half came through and higher fish oil prices lifted omega-3 DHA prices. For the first nine months, sales were € 971.6 million (+3.9% organic), adjusted EBITDA € 152.9 million (15.7% margin) and free cash flow € 57 million. Guidance was maintained at +3-6% organic sales growth, adjusted EBITDA margin above 16% (cut in July from around 17% on Middle East-driven sulfuric acid costs) and free cash flow of € 85-90 million.

## Investments and deals

- **Algae oil capacity in Brazil**: The Orindiúva capacity expansion is complete and a new fermenter adds capacity in 2027; a decision on debottlenecking or a brownfield investment is due by end-2026.
- **Food footprint expansion**: Expanded fermentation and vinegar capacity in Montgomery (US), new dairy and bakery labs, a fully operational Querétaro (Mexico) facility, and application capabilities in Singapore and India.
- **Capex plan**: Capex was € 68.5 million in 2025, mainly Nutrition capacity and vinegar insourcing; the 2026 plan was about € 85 million.
- **Innovation partnerships and botanicals**: Partnerships with BRAIN Biotech, Kuehnle AgroSystems and Phycom, and an intent to add botanical extraction technologies such as rosemary extracts.
- **PLA joint venture stake kept**: The sale of the TotalEnergies Corbion stake started after November 2025 was ended in October 2026; Corbion will keep developing the business.

## Challenges and risks

- **Middle East input costs**: Higher sulfuric acid costs have a gross impact of €15 million to €20 million in 2026 and are expected to stay elevated in 2027.
- **Soft core food demand**: Bakery and meat demand stayed soft, and after SNAP support was withdrawn US customers asked for more affordable recipes.
- **Lactic acid competition**: Global imbalances of lactic acid supply and demand are a top risk, alongside raw material and energy price volatility (sugar is 28% of raw material spend).
- **Geopolitics, tariffs and currency**: Tariffs and inflation are top risks; a 1% depreciation of the US dollar against the euro reduces EBITDA by about € 2.4 million.
- **Customer concentration in omega-3**: A few large aquaculture customers drive Nutrition volumes, which caused weak Q1 2026 phasing.

## What leadership says

> "our natural preservation platform continues to win. Especially as customers look for cleaner label, regulation-ready solutions." — Olivier Rigaud, CEO, Q2/H1 2026 results call, 31 July 2026

> "why we are pushing hard to grow beyond aquaculture into pet nutrition and human nutrition." — Olivier Rigaud, CEO, FY/Q4 2025 results call, 26 February 2026

> "I am proud to report that our team delivered strong results, reflecting the high demand for our portfolio and disciplined execution across the businesses." — Olivier Rigaud, CEO, Q3 2026 Interim Management Statement, 28 October 2026

> "predominantly driven by the Middle East situation" — Peter Kazius, CFO, Q2/H1 2026 results call, 31 July 2026, on the margin guidance cut


## Where a supplier can help

- **Alternative inputs and procurement**: Tied to the Middle East input-cost challenge: suppliers of sulfuric acid alternatives, energy or commodity risk tools can help protect the 2026 margin guidance.
- **Fermentation and refining capacity**: Tied to the algae oil capacity decision and Brazil fermenter: engineering, bioprocess equipment and refining suppliers fit the debottlenecking or brownfield choice.
- **Food safety and modeling tools**: Tied to the natural preservation priority and Listeria regulation: lab, testing and data-modeling partners can support application development for customers.
- **Pet and human nutrition channels**: Tied to diversifying omega-3 beyond aquaculture: distributors and formulators in pet food and supplements can open new customers.
- **Application labs in growth regions**: Tied to the food footprint expansion in Mexico, Singapore and India: lab equipment and service providers can support new application capabilities.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Corbion Annual Report 2025](https://annualreport.corbion.com/external/asset/download/project/f9ad1d0a-03ec-0000-4e86-a7d843474a8a/name/Corbion_annual_report_2025.pdf)

Annual report · 2026-03-17

- Corbion is an Amsterdam-listed (Euronext) sustainable food-ingredient company built on fermentation and lactic acid: 2025 sales of € 1,267.4 million and a workforce of 2,408 FTE, with plants in the US, Thailand, Brazil, Mexico, the Netherlands and Spain.
- Two segments: Functional Ingredients & Solutions (Food, Biochemicals, Lactic Acid to the PLA joint venture; € 970.4 million sales, 11.1% adjusted EBITDA margin) and Health & Nutrition (algae omega-3 Nutrition, Pharma, Biomaterials; € 297.0 million sales, 32.5% margin).
- 2025: organic sales growth +2.2% (volume/mix +3.4%, price -1.2%, currency -3.5%); adjusted EBITDA € 204.3 million (+26.7% organic), margin 16.1% (2024: 13.6%); result after taxes € 74.8 million; EPS € 1.29 (2024: € 0.79).
- Free cash flow € 90.8 million, capex € 68.5 million; covenant net debt/EBITDA down from 2.1x to 1.5x; proposed dividend € 1.00 per share (€ 0.64 regular + € 0.36 special).
- Advance 2025 closed with all main targets met; BRIGHT 2030 (announced November 2025) targets 3-6% organic sales growth per year, ~18% adjusted EBITDA margin by 2028 and € 270 million cumulative free cash flow over 2026-2028.
- Growth bets: natural (label-friendly) preservation, algae omega-3 beyond aquaculture into pet food and human nutrition (AlgaPrime DHA, AlgaVia), and resorbable Biomaterials (PURASORB, MedinCell/Teva olanzapine injectable).
- Corbion started a plan to sell its interest in the TotalEnergies Corbion 50/50 PLA joint venture (Luminy PLA) after the November 2025 Capital Markets Day.
- 2026 outlook: organic sales growth 3-6%, adjusted EBITDA margin up ~+100bps to ~17%, free cash flow € 85-90 million, capex ~80 million, double-digit adjusted EPS growth; EBITDA weighted to H2.
- Top risks: geopolitical tension and tariffs, lactic acid competition and overcapacity, raw material/energy price volatility (sugar is 28% of raw material spend), supply chain disruption, product safety, cybersecurity.
- CEO Olivier Rigaud (since 2019); CFO Peter Kazius; new CTO Yves Boland and Chief Integrated Supply Chain Officer Oli Arnason joined in 2025; Supervisory Board chaired by Ilona Haaijer.

### [Corbion Q3 2026 Interim Management Statement](https://www.corbion.com/-/media/corbion/files/quarterly/2026/2026-10-28_corbion_press-release_q3-2026.pdf)

Interim report · 2026-10-28

- Q3 2026 (to 30 September): sales € 340.5 million (+9.3%), organic growth +7.6% (volume/mix +7.9%, price -0.3%); adjusted EBITDA € 64.1 million (+28.2% organic), margin 18.8% vs 15.9%.
- Nine months: sales € 971.6 million (+3.9% organic), adjusted EBITDA € 152.9 million, margin 15.7% (16.3% a year earlier), operating profit € 81.4 million (-10.9%), free cash flow € 57 million.
- Functional Ingredients & Solutions: YTD sales € 748.7 million, organic +3.8%; Q3 margin 12.5% (+170 bps) on sugar cost reduction and cost initiatives; growth in vinegars, high-protein bread, Biochemicals and Lactic Acid to PLA; meat demand soft.
- Health & Nutrition: Q3 organic sales +20.0% as Nutrition volumes phased from H1 came through; higher fish oil prices lifted omega-3 DHA prices; Q3 margin 38.1%.
- The FDA approved Teva/Medincell's once-monthly olanzapine injectable (WELTRUZA), supporting Biomaterials growth; Pharma sales fell on destocking in North and Latin America.
- Corbion ended the sale process for its TotalEnergies Corbion PLA joint venture stake: offers "did not adequately reflect" its value; the JV's YTD sales rose 24.2% organically.
- FY2026 guidance maintained: organic sales growth +3-6%, adjusted EBITDA margin >16%, free cash flow € 85-90 million; Q4 FI&S margin hit by Middle East conflict costs.

### [Corbion FY/Q4 2025 results call transcript](https://www.corbion.com/-/media/corbion/files/quarterly/2025/2026-02-27_fy-q4-2025_transcript.pdf)

Executive talk · Olivier Rigaud, CEO (with Peter Kazius, CFO) · 2026-02-26

- CEO Olivier Rigaud: "2025 was a strong year for Corbion": volume/mix +3.4% for the year and 8.8% in Q4; adjusted EBITDA EUR204 million, organic growth of nearly 27%; free cash flow EUR91 million; EPS EUR1.29.
- BRIGHT 2030: invest in natural preservation, nutrition and biomedical polymers, reduce non-core lactic acid exposures, review options for PLA; 3% to 6% organic growth, 18% margin by 2028, EUR270 million free cash flow over three years, 13% ROCE.
- 2026 guidance: organic sales growth 3-6%, adjusted EBITDA margin approximately 17%, capex approximately €85 million, double-digit adjusted EPS growth (CFO: "closer to 10%"), EBITDA weighted to H2.
- Omega-3: roughly two-thirds under longer-term contracts; fish oil rose from around USD 3,000 per ton in Q3 to close to USD 4,000 in Q4; industry talk of a fish-oil supply deficit of around 50,000 tons by end-2026; Q1 2026 hit by customer phasing in concentrated aquaculture.
- US demand split: after SNAP support was withdrawn, customers ask for cheaper recipes (soft bakery and meat), while GLP-1 and MAHA trends drive demand for high-protein, high-fiber and mineral-fortified products.
- Sugar is hedged fully for 2026 and for almost three quarters of '27; margin levers to 18% are input costs, faster growth in H&N specialties and returns on the Thai lactic acid plant.
- PLA joint venture sale "on track", update expected by mid-2026; dividend €1.00 (€0.64 regular plus €0.36 special).
- Rosemary and botanical extracts are "complementary" to lactic acid; Corbion wants to add botanical extraction technologies.

### [Corbion Q2/H1 2026 results call transcript](https://www.corbion.com/-/media/corbion/files/quarterly/2026/2026-08-04_q2h1-2026_transcript.pdf)

Executive talk · Olivier Rigaud, CEO (with Peter Kazius, CFO) · 2026-07-31

- H1 2026: sales €631.1 million, organic growth +2.1% (volume/mix +4.0%, price -1.9%, currency -4.3%); Q2 accelerated to +8.5% organic, sales €337.4 million.
- Adjusted EBITDA €88.8 million in H1 (organic -8.0%) and €51.0 million in Q2 (+4.2% organic); operating profit €42.1 million; free cash flow negative €4.0 million.
- FY2026 adjusted EBITDA margin guidance cut to above 16% from around 17%, "predominantly driven by the Middle East situation": sulfuric acid costs now a gross impact of €15 million to €20 million; sales growth (+3% to +6%) and free cash flow (€85-90 million) guidance kept.
- Omega-3: fish meal and fish oil prices up more than 60% year on year as Peru cut quotas; CEO calls algae omega-3 "an increasingly necessary solution"; long-term aquaculture contracts priced at €4,000-€5,000 end in December 2026 and are being renegotiated at higher prices.
- Health & Nutrition margin 27.5% in H1, expected slightly above 30% for the year; FI&S margin up +250 basis points versus Q1.
- PLA joint venture volumes up more than 20% in H1 and 44% in Q2, driven by industrial 3D printing in China; sale process continuing.
- Food wins in North America in high-protein products linked to GLP-1 reformulation; sugar almost fully hedged for 2027 and early 2028.
- New fermenter in Brazil adds capacity in 2027; algae oil capacity sufficient until end-2028 or early 2029, with a decision on further debottlenecking or a brownfield investment due.

## Questions about Corbion

### What does Corbion do?

Corbion makes fermentation-based ingredients: lactic acid and derivatives, natural food preservation systems, algae omega-3 for aquaculture, pets and people, pharma ingredients and resorbable biomaterials.

### What is Corbion's revenue?

Corbion's 2025 sales were € 1,267.4 million with adjusted EBITDA of € 204.3 million; sales for the first nine months of 2026 were € 971.6 million.

### How many employees does Corbion have?

Corbion had a workforce of 2,408 FTE at the end of 2025.

### Who leads Corbion?

Olivier Rigaud has been CEO since August 2019, with Peter Kazius as CFO since May 2024; the Supervisory Board is chaired by Ilona Haaijer.

### What is Corbion's strategy?

BRIGHT 2030 focuses on natural preservation, nutrition and biomaterials, targeting 3-6% organic sales growth a year and an adjusted EBITDA margin of approximately 18% by 2028.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
